RELX PLC (LON:REL)
London · Delayed Price · Currency is GBP · Price in GBX 3,936.00
+29.00 (0.74%)
Jul 31, 2025, 4:49 PM BST
Marinus Pharmaceuticals Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 9,534 | 9,434 | 9,161 | 8,553 | 7,244 | 7,110 | Upgrade | |
Revenue Growth (YoY) | 2.48% | 2.98% | 7.11% | 18.07% | 1.88% | -9.70% | Upgrade |
Cost of Revenue | 3,291 | 3,300 | 3,216 | 3,045 | 2,562 | 2,487 | Upgrade |
Gross Profit | 6,243 | 6,134 | 5,945 | 5,508 | 4,682 | 4,623 | Upgrade |
Selling, General & Admin | 3,368 | 3,317 | 3,310 | 3,209 | 2,836 | 2,876 | Upgrade |
Operating Expenses | 3,368 | 3,317 | 3,310 | 3,209 | 2,836 | 2,876 | Upgrade |
Operating Income | 2,875 | 2,817 | 2,635 | 2,299 | 1,846 | 1,747 | Upgrade |
Interest Expense | -362 | -281 | -300 | -182 | -125 | -151 | Upgrade |
Interest & Investment Income | 11 | 6 | 8 | 4 | 1 | 3 | Upgrade |
Earnings From Equity Investments | 44 | 43 | 46 | 19 | 29 | 15 | Upgrade |
Other Non Operating Income (Expenses) | -22 | -22 | -22 | -18 | -9 | -13 | Upgrade |
EBT Excluding Unusual Items | 2,546 | 2,563 | 2,367 | 2,122 | 1,742 | 1,601 | Upgrade |
Impairment of Goodwill | -36 | -36 | -42 | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | -2 | -2 | -11 | 9 | 16 | 151 | Upgrade |
Gain (Loss) on Sale of Assets | 37 | 32 | -19 | -18 | 39 | -21 | Upgrade |
Asset Writedown | - | - | - | - | - | -103 | Upgrade |
Other Unusual Items | - | - | - | - | - | -145 | Upgrade |
Pretax Income | 2,545 | 2,557 | 2,295 | 2,113 | 1,797 | 1,483 | Upgrade |
Income Tax Expense | 608 | 613 | 507 | 481 | 326 | 275 | Upgrade |
Earnings From Continuing Operations | 1,937 | 1,944 | 1,788 | 1,632 | 1,471 | 1,208 | Upgrade |
Minority Interest in Earnings | -12 | -10 | -7 | 2 | - | 16 | Upgrade |
Net Income | 1,925 | 1,934 | 1,781 | 1,634 | 1,471 | 1,224 | Upgrade |
Net Income to Common | 1,925 | 1,934 | 1,781 | 1,634 | 1,471 | 1,224 | Upgrade |
Net Income Growth | 1.74% | 8.59% | 9.00% | 11.08% | 20.18% | -18.67% | Upgrade |
Shares Outstanding (Basic) | 1,852 | 1,866 | 1,892 | 1,919 | 1,928 | 1,926 | Upgrade |
Shares Outstanding (Diluted) | 1,862 | 1,877 | 1,903 | 1,929 | 1,939 | 1,938 | Upgrade |
Shares Change (YoY) | -1.48% | -1.37% | -1.37% | -0.52% | 0.08% | -0.94% | Upgrade |
EPS (Basic) | 1.04 | 1.04 | 0.94 | 0.85 | 0.76 | 0.64 | Upgrade |
EPS (Diluted) | 1.03 | 1.03 | 0.94 | 0.85 | 0.76 | 0.63 | Upgrade |
EPS Growth | 3.29% | 10.15% | 10.51% | 11.74% | 19.94% | -17.82% | Upgrade |
Free Cash Flow | 2,739 | 2,588 | 2,427 | 2,365 | 1,988 | 1,553 | Upgrade |
Free Cash Flow Per Share | 1.47 | 1.38 | 1.27 | 1.23 | 1.02 | 0.80 | Upgrade |
Dividend Per Share | 0.643 | 0.630 | 0.588 | 0.546 | 0.498 | 0.470 | Upgrade |
Dividend Growth | 7.17% | 7.14% | 7.69% | 9.64% | 5.96% | 2.84% | Upgrade |
Gross Margin | 65.48% | 65.02% | 64.89% | 64.40% | 64.63% | 65.02% | Upgrade |
Operating Margin | 30.15% | 29.86% | 28.76% | 26.88% | 25.48% | 24.57% | Upgrade |
Profit Margin | 20.19% | 20.50% | 19.44% | 19.10% | 20.31% | 17.21% | Upgrade |
Free Cash Flow Margin | 28.73% | 27.43% | 26.49% | 27.65% | 27.44% | 21.84% | Upgrade |
EBITDA | 3,093 | 3,047 | 2,894 | 2,640 | 2,195 | 2,183 | Upgrade |
EBITDA Margin | 32.44% | 32.30% | 31.59% | 30.87% | 30.30% | 30.70% | Upgrade |
D&A For EBITDA | 218 | 230 | 259 | 341 | 349 | 436 | Upgrade |
EBIT | 2,875 | 2,817 | 2,635 | 2,299 | 1,846 | 1,747 | Upgrade |
EBIT Margin | 30.15% | 29.86% | 28.76% | 26.88% | 25.48% | 24.57% | Upgrade |
Effective Tax Rate | 23.89% | 23.97% | 22.09% | 22.76% | 18.14% | 18.54% | Upgrade |
Updated Feb 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.